Objective:
To discuss newly FDA-approved lasers for refractive surgery, including their performance and implications for clinical practice.
Key Findings:
- Last FDA approval of an excimer laser was in 2011.
- Current lasers have high-speed repetition rates at 500 Hz.
- More than one-third of eyes gained 1 or more lines of corrected distance visual acuity post-surgery.
- All eyes treated with ray tracing-guided LASIK were 20/20 or better at 1 and 3 months.
Interpretation:
The advancements in laser technology and FDA approvals indicate a resurgence in refractive surgery options, which may significantly enhance surgical precision and improve patient outcomes.
Limitations:
- Data primarily from FDA trials may not reflect broader clinical practice outcomes, potentially limiting generalizability.
- Surgeons may require adjustment periods for new technologies, which could impact initial patient experiences.
Conclusion:
Surgeons should consider treatment indications, clinic logistics, and specific patient needs when selecting new laser technologies for refractive surgery.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.